Switch theme
Sign up to access all valuation multiples
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
2006
108
LTM Revenue $46.6M
LTM EBITDA -$34.5M
$6.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Precision BioSciences has a last 12-month revenue (LTM) of $46.6M and a last 12-month EBITDA of -$34.5M.
In the most recent fiscal year, Precision BioSciences achieved revenue of $68.7M and an EBITDA of $13.5M.
Precision BioSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Precision BioSciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $46.6M | XXX | $68.7M | XXX | XXX | XXX |
| Gross Profit | $46.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$34.5M | XXX | $13.5M | XXX | XXX | XXX |
| EBITDA Margin | -74% | XXX | 20% | XXX | XXX | XXX |
| EBIT | -$46.2M | XXX | -$26.2M | XXX | XXX | XXX |
| EBIT Margin | -99% | XXX | -38% | XXX | XXX | XXX |
| Net Profit | -$25.0M | XXX | $7.2M | XXX | XXX | XXX |
| Net Margin | -54% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Precision BioSciences's stock price is $5.
Precision BioSciences has current market cap of $53.6M, and EV of $6.1M.
See Precision BioSciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.1M | $53.6M | XXX | XXX | XXX | XXX | $-2.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Precision BioSciences has market cap of $53.6M and EV of $6.1M.
Precision BioSciences's trades at 0.1x EV/Revenue multiple, and 0.4x EV/EBITDA.
Equity research analysts estimate Precision BioSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Precision BioSciences has a P/E ratio of -2.1x.
See valuation multiples for Precision BioSciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $53.6M | XXX | $53.6M | XXX | XXX | XXX |
| EV (current) | $6.1M | XXX | $6.1M | XXX | XXX | XXX |
| EV/Revenue | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.1x | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | 0.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | 7.5x | XXX | XXX | XXX |
| EV/FCF | -0.1x | XXX | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPrecision BioSciences's last 12 month revenue growth is -61%
Precision BioSciences's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.9M for the same period.
Precision BioSciences's rule of 40 is -126% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Precision BioSciences's rule of X is -226% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Precision BioSciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -61% | XXX | -43% | XXX | XXX | XXX |
| EBITDA Margin | -74% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -126% | XXX | -41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -226% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 87% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 138% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Precision BioSciences acquired XXX companies to date.
Last acquisition by Precision BioSciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Precision BioSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Precision BioSciences founded? | Precision BioSciences was founded in 2006. |
| Where is Precision BioSciences headquartered? | Precision BioSciences is headquartered in United States of America. |
| How many employees does Precision BioSciences have? | As of today, Precision BioSciences has 108 employees. |
| Who is the CEO of Precision BioSciences? | Precision BioSciences's CEO is Mr. Michael Amoroso. |
| Is Precision BioSciences publicy listed? | Yes, Precision BioSciences is a public company listed on NAS. |
| What is the stock symbol of Precision BioSciences? | Precision BioSciences trades under DTIL ticker. |
| When did Precision BioSciences go public? | Precision BioSciences went public in 2019. |
| Who are competitors of Precision BioSciences? | Similar companies to Precision BioSciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Precision BioSciences? | Precision BioSciences's current market cap is $53.6M |
| What is the current revenue of Precision BioSciences? | Precision BioSciences's last 12 months revenue is $46.6M. |
| What is the current revenue growth of Precision BioSciences? | Precision BioSciences revenue growth (NTM/LTM) is -61%. |
| What is the current EV/Revenue multiple of Precision BioSciences? | Current revenue multiple of Precision BioSciences is 0.1x. |
| Is Precision BioSciences profitable? | Yes, Precision BioSciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Precision BioSciences? | Precision BioSciences's last 12 months EBITDA is -$34.5M. |
| What is Precision BioSciences's EBITDA margin? | Precision BioSciences's last 12 months EBITDA margin is -74%. |
| What is the current EV/EBITDA multiple of Precision BioSciences? | Current EBITDA multiple of Precision BioSciences is -0.2x. |
| What is the current FCF of Precision BioSciences? | Precision BioSciences's last 12 months FCF is -$42.3M. |
| What is Precision BioSciences's FCF margin? | Precision BioSciences's last 12 months FCF margin is -91%. |
| What is the current EV/FCF multiple of Precision BioSciences? | Current FCF multiple of Precision BioSciences is -0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
